The consumer advocacy group Public Citizen is asking the U.S. Food and Drug Administration the take Novo Nordisk's diabetes drug Victoza, alleging the drug poses a risk to the public, according to a Dow Jones Newswire report.
The FDA approved the drug Victoza for commercial distribution in 2010, saying its effectiveness in treating type-2 diabetes outweighed potential risk of pancreatitis and thyroid cancer. However, an analysis of adverse events reported to the FDA reveals 200 cases of acute pancreatitis and 26 cases of thyroid tumors associated with the drug.
Public Citizen filed petition yesterday to have the drug pulled off the market. Neither the FDA nor Novo Nordisk has responded to the filing.
The FDA approved the drug Victoza for commercial distribution in 2010, saying its effectiveness in treating type-2 diabetes outweighed potential risk of pancreatitis and thyroid cancer. However, an analysis of adverse events reported to the FDA reveals 200 cases of acute pancreatitis and 26 cases of thyroid tumors associated with the drug.
Public Citizen filed petition yesterday to have the drug pulled off the market. Neither the FDA nor Novo Nordisk has responded to the filing.
More Articles on Medication Safety:
Adena Medical Center Back in Compliance With CMS Standards for Quality
West Calcasieu Cameron Hospital Uses Bar Code Wristbands to Prevent Medication Errors
Women's Clinic Loses License For Lack of Policies on Medication Errors, Other Shortfalls